Hyman, David M <br/><br/>
Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  06 2018 
 - 2749-2757 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-17-1775  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiopoietin-2--antagonists & inhibitors<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab--administration & dosage<br/>Carboplatin--administration & dosage<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Neoplasms--diagnosis<br/>Paclitaxel--administration & dosage<br/>Treatment Outcome<br/>Young Adult